Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab study

02/02/2021 | 11:01pm EDT

BEIJING, Feb 3 (Reuters) - Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.

Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.

Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.

The paper was written by researchers from Sinopharm-affiliated Beijing Institute of Biological Products, the Institute of Microbiology of Chinese Academy of Sciences, which is co-developing a candidate with Zhifei unit, and two other Chinese agencies.

However, the samples' activity against the variant was weaker than against the original virus and another variant currently spreading globally, according to the paper published on website BioRxiv ahead its peer-review. https://bit.ly/3rfr2UZ

The activity reduction "should be taken into account for its impact for the clinical efficacy of these vaccines," they said.

The Sinopharm vaccine is approved in China for general public use and is also used in several other countries including the United Arab Emirates. The Zhifei shot is in late-stage clinical trials in China and overseas.

Preliminary clinical trial data on vaccines from Novavax Inc and Johnson & Johnson also showed they were significantly less effective at preventing COVID-19 in trial participants in South Africa, where the potent new variant is widespread. (Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim & Simon Cameron-Moore)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 1.50% 157.89 End-of-day quote.6.75%
DOW JONES AFRICA TITANS 50 INDEX -0.30% 524.29 Delayed Quote.-0.80%
DOW JONES SOUTH AFRICA(ZAR) -0.35% 1917.51 Delayed Quote.8.72%
NOVAVAX, INC. -2.54% 179.33 Delayed Quote.60.82%
S&P AFRICA 40 INDEX -0.32% 169.63 Delayed Quote.-1.87%
SINOPHARM GROUP CO., LTD. -1.69% 20.4 End-of-day quote.8.17%
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
07/18CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : Zhifei Biological's COVID-19 Vaccine Reta..
MT
06/28Are Chinese COVID-19 shots effective against the Delta variant?
RE
06/11Chongqing Zhifei Biological Products Co., Ltd. Approves 2020 Profit Distribut..
CI
06/09China to study using CanSinoBIO COVID shots as a booster
RE
05/06Shares of China vaccine makers slump on U.S. waiver support
RE
04/20Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Dividend for th..
CI
04/19Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for t..
CI
04/19CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China trials mixing of CanSinoBIO's and Z..
RE
03/15CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China IMCAS's COVID-19 vaccine obtained e..
RE
02/02Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect..
RE
More news
Financials
Sales 2021 26 005 M 4 025 M 4 025 M
Net income 2021 7 311 M 1 132 M 1 132 M
Net cash 2021 4 294 M 665 M 665 M
P/E ratio 2021 34,9x
Yield 2021 0,69%
Capitalization 253 B 39 096 M 39 100 M
EV / Sales 2021 9,55x
EV / Sales 2022 7,39x
Nbr of Employees 3 380
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 157,89 CNY
Average target price 224,93 CNY
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer & Director
Yu Qin Wu Chairman-Supervisory Board
Xin Rong Zhang Independent Director
Bao Kui Liu Independent Director
Sector and Competitors